The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC).
 
Bo Wang
Stock and Other Ownership Interests - Roche/Genentech (I)
Consulting or Advisory Role - AstraZeneca; BeiGene; EMD Serono
Speakers' Bureau - EMD Serono
 
Kartik Konduri
Consulting or Advisory Role - Amgen; AstraZeneca; EMD Serono; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; squibb; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Takeda
 
Robert Jotte
Leadership - Sarah Cannon Research Institute
Consulting or Advisory Role - AstraZeneca
 
Donald Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Rachel Sanborn
Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; OSE Immunotherapeutics; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
Travel, Accommodations, Expenses - Hotspot Therapeutics; Hotspot Therapeutics
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
David Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AVEO; AZTherapies; Bayer; Bristol-Myers Squibb; Daiichi; Eisai; EMD Serono; Exelixis; Fresenius Kabi; Gilead Sciences; Janssen Oncology; Lilly; McGivney Global Advisors; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Seagen; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Katherin Combs
Employment - Genprex
Stock and Other Ownership Interests - Genprex
 
Jacqueline Opiola
Employment - Genprex
Stock and Other Ownership Interests - Genprex
 
Mark Berger
Employment - Genprex
Leadership - Genprex
Stock and Other Ownership Interests - Genprex
Patents, Royalties, Other Intellectual Property - Am holder of patents at Genprex Inc. that do not provide for any payments to me
 
Daniel Morgensztern
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bayer; Bristol-Myers Squibb/Medarex; G1 Therapeutics; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Genprex (Inst); Heat Biologics (Inst); Hybercell (Inst); ImmunityBio (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Genprex